Aug. 15 (Reuters) – Novavax Inc mentioned on Monday it experienced utilized for authorization in the United States to use its COVID-19 vaccine as a booster dose in people today who had acquired its injections or a various vaccine.
The ask for to the United States Meals and Drug Administration (Fda) comes due to the slowness of its implementation in this state, the place the Novavax vaccine was authorized in July, inspite of expectations that it would encourage vaccine skeptics to inoculate.
“It is critical that people have a choice when thinking of how to safeguard them selves from COVID-19,” said CEO Stanley Erck in a assertion, referring to the Novavax vaccine employing standard know-how.
It is a protein-dependent vaccine that makes use of purified fragments of the virus to stimulate an immune reaction, a engineering that has been utilised to combat illnesses this kind of as hepatitis B and the flu.
A lot more than 9,700 vaccine doses have been administered in the United States so far, out of a whole of 606 million doses administered over-all. A lot more than 67% of the U.S. populace has acquired two doses of the COVID-19 vaccine, according to the most recent federal knowledge.
Very last 7 days the firm halved its comprehensive-12 months profits forecast as it does not be expecting significant revenue of its COVID-19 vaccine this calendar year in the United States, because of to oversupply and weak desire.
Novavax stock was up 1.9% to $ 42.26 by 1345 GMT.
(Reporting by Manas Mishra in Bengaluru Spanish editing by Ricardo Figueroa)
–
